Charles Dunn

Charles joined SV in 2018 and is a Principal in the biotech team. He helps form and fund companies developing transformational new medicines, with a broad focus from new company creation to later stage public and private opportunities. Charles serves as a Board Director at Imbria Pharmaceuticals, as well as at Mestag Therapeutics and an SV-created stealth psychiatry newco which he incubated and launched as the deal lead. He is also Board Observer at Autifony Therapeutics and Pulmocide.

Prior to joining SV, Charles qualified as an ACA after three years at Deloitte, with a focus on Life Sciences clients including SV portfolio companies and has an academic background in human genetics & molecular biology (UCL). Charles holds a MSci Human Genetics, University College London (UCL) and is a chartered accountant (ACA).